{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T16:01:39Z","timestamp":1794499299096,"version":"4.9.1"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,19]],"date-time":"2022-07-19T00:00:00Z","timestamp":1658188800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","prd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Parkinsonism &amp; Related Disorders"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.parkreldis.2022.07.008","type":"journal-article","created":{"date-parts":[[2022,7,18]],"date-time":"2022-07-18T22:32:18Z","timestamp":1658183538000},"page":"111-116","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"special_numbering":"C","title":["The relationship between plasma biomarkers and amyloid PET in dementia with Lewy bodies"],"prefix":"10.1016","volume":"101","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7195-4846","authenticated-orcid":false,"given":"Paul C.","family":"Donaghy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9536-0185","authenticated-orcid":false,"given":"Michael","family":"Firbank","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Petrides","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5569-938X","authenticated-orcid":false,"given":"Jim","family":"Lloyd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Barnett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsty","family":"Olsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Heslegrave","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3930-4354","authenticated-orcid":false,"given":"Henrik","family":"Zetterberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan J.","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John T.","family":"O'Brien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.parkreldis.2022.07.008_bib1","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.jagp.2019.12.009","article-title":"Amyloid imaging and longitudinal clinical progression in dementia with lewy bodies","volume":"28","author":"Donaghy","year":"2020","journal-title":"Am. J. Geriatr. Psychiatr. : Off. J. Am. Assoc. Geriatric Psychiatr."},{"issue":"Pt 10","key":"10.1016\/j.parkreldis.2022.07.008_bib2","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.1093\/brain\/aww193","article-title":"Amyloid-beta deposition and regional grey matter atrophy rates in dementia with Lewy bodies","volume":"139","author":"Sarro","year":"2016","journal-title":"Brain : J. Neurol."},{"key":"10.1016\/j.parkreldis.2022.07.008_bib3","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.parkreldis.2020.09.030","article-title":"Prevalence and clinical associations of tau in Lewy body dementias: a systematic review and meta-analysis","volume":"80","author":"Chin","year":"2020","journal-title":"Park. Relat. Disord."},{"issue":"21","key":"10.1016\/j.parkreldis.2022.07.008_bib4","doi-asserted-by":"crossref","first-page":"12245","DOI":"10.1073\/pnas.211412398","article-title":"beta-amyloid peptides enhance alpha-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease","volume":"98","author":"Masliah","year":"2001","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"5619","key":"10.1016\/j.parkreldis.2022.07.008_bib5","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1126\/science.1082324","article-title":"Initiation and synergistic fibrillization of tau and alpha-synuclein","volume":"300","author":"Giasson","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.parkreldis.2022.07.008_bib6","doi-asserted-by":"crossref","DOI":"10.1002\/alz.12618","article-title":"Biofluid-based biomarkers for Alzheimer's disease-related pathologies: an update and synthesis of the literature","author":"Zetterberg","year":"2022","journal-title":"Alzheimer's Dementia : J. Alzheimer's Assoc."},{"issue":"1","key":"10.1016\/j.parkreldis.2022.07.008_bib7","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/S1474-4422(21)00361-6","article-title":"Blood-based biomarkers for Alzheimer's disease: towards clinical implementation","volume":"21","author":"Teunissen","year":"2022","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.parkreldis.2022.07.008_bib8","doi-asserted-by":"crossref","DOI":"10.1136\/jnnp-2021-327788","article-title":"Differential levels of plasma biomarkers of neurodegeneration in Lewy body dementia, Alzheimer's disease, frontotemporal dementia and progressive supranuclear palsy","author":"Chouliaras","year":"2022","journal-title":"J. Neurol. Neurosurg. Psychiatr."},{"issue":"1","key":"10.1016\/j.parkreldis.2022.07.008_bib9","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1001\/jamaneurol.2021.4222","article-title":"Association of plasma p-tau181 and p-tau231 concentrations with cognitive decline in patients with probable dementia with lewy bodies","volume":"79","author":"Gonzalez","year":"2022","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.parkreldis.2022.07.008_bib10","doi-asserted-by":"crossref","DOI":"10.1002\/mds.28994","article-title":"A longitudinal study of plasma pTau181 in mild cognitive impairment with lewy bodies and alzheimer's disease","author":"Thomas","year":"2022","journal-title":"Mov. Disord. : off. J. Movement Disorder Soc."},{"issue":"7","key":"10.1016\/j.parkreldis.2022.07.008_bib11","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1002\/mds.27403","article-title":"Clinical and imaging correlates of amyloid deposition in dementia with Lewy bodies","volume":"33","author":"Donaghy","year":"2018","journal-title":"Mov. Disord.: off. J. Movement Disorder Soc."},{"issue":"12","key":"10.1016\/j.parkreldis.2022.07.008_bib12","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1212\/01.wnl.0000187889.17253.b1","article-title":"Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium","volume":"65","author":"McKeith","year":"2005","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.parkreldis.2022.07.008_bib13","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1212\/WNL.0000000000004058","article-title":"Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB Consortium","volume":"89","author":"McKeith","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2022.07.008_bib14","series-title":"Florbetapir Processing Methods","author":"Landau","year":"2014"},{"issue":"3","key":"10.1016\/j.parkreldis.2022.07.008_bib15","doi-asserted-by":"crossref","first-page":"378","DOI":"10.2967\/jnumed.111.090340","article-title":"Performance characteristics of amyloid PET with florbetapir F 18 in patients with alzheimer's disease and cognitively normal subjects","volume":"53","author":"Joshi","year":"2012","journal-title":"J. Nucl. Med. : Off. Publ. Soc. Nuclear Med."},{"issue":"17","key":"10.1016\/j.parkreldis.2022.07.008_bib16","doi-asserted-by":"crossref","first-page":"e1647","DOI":"10.1212\/WNL.0000000000008081","article-title":"High-precision plasma beta-amyloid 42\/40 predicts current and future brain amyloidosis","volume":"93","author":"Schindler","year":"2019","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.parkreldis.2022.07.008_bib17","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/s41591-020-0762-2","article-title":"Diagnostic value of plasma phosphorylated tau181 in Alzheimer's disease and frontotemporal lobar degeneration","volume":"26","author":"Thijssen","year":"2020","journal-title":"Nat. Med."},{"issue":"3","key":"10.1016\/j.parkreldis.2022.07.008_bib18","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/s41591-020-0755-1","article-title":"Plasma P-tau181 in Alzheimer's disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer's dementia","volume":"26","author":"Janelidze","year":"2020","journal-title":"Nat. Med."},{"issue":"3","key":"10.1016\/j.parkreldis.2022.07.008_bib19","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1002\/mds.28370","article-title":"Plasma phospho-tau identifies alzheimer's Co-pathology in patients with lewy body disease","volume":"36","author":"Hall","year":"2021","journal-title":"Mov. Disord.: off. J. Movement Disorder Soc."},{"issue":"8","key":"10.1016\/j.parkreldis.2022.07.008_bib20","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.jalz.2018.02.013","article-title":"Plasma phospho-tau181 increases with Alzheimer's disease clinical severity and is associated with tau- and amyloid-positron emission tomography","volume":"14","author":"Mielke","year":"2018","journal-title":"Alzheimer's Dementia: J. Alzheimer's Assoc."},{"issue":"3","key":"10.1016\/j.parkreldis.2022.07.008_bib21","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.neurobiolaging.2013.09.035","article-title":"Glial fibrillary acidic protein isoform expression in plaque related astrogliosis in Alzheimer's disease","volume":"35","author":"Kamphuis","year":"2014","journal-title":"Neurobiol. Aging"},{"issue":"12","key":"10.1016\/j.parkreldis.2022.07.008_bib22","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1001\/jamaneurol.2021.3671","article-title":"Differences between plasma and cerebrospinal fluid glial fibrillary acidic protein levels across the alzheimer disease continuum","volume":"78","author":"Benedet","year":"2021","journal-title":"JAMA Neurol."},{"issue":"8","key":"10.1016\/j.parkreldis.2022.07.008_bib23","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1136\/jnnp-2018-320106","article-title":"Neurofilament light chain as a biomarker in neurological disorders","volume":"90","author":"Gaetani","year":"2019","journal-title":"J. Neurol. Neurosurg. Psychiatr."},{"issue":"8","key":"10.1016\/j.parkreldis.2022.07.008_bib24","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1002\/mds.26668","article-title":"Alzheimer's disease cerebrospinal fluid biomarkers predict cognitive decline in lewy body dementia","volume":"31","author":"Abdelnour","year":"2016","journal-title":"Mov. Disord.: off. J. Movement Disorder Soc."}],"container-title":["Parkinsonism &amp; Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802022002255?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802022002255?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T00:25:57Z","timestamp":1761179157000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1353802022002255"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":24,"alternative-id":["S1353802022002255"],"URL":"https:\/\/doi.org\/10.1016\/j.parkreldis.2022.07.008","relation":{},"ISSN":["1353-8020"],"issn-type":[{"value":"1353-8020","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The relationship between plasma biomarkers and amyloid PET in dementia with Lewy bodies","name":"articletitle","label":"Article Title"},{"value":"Parkinsonism & Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.parkreldis.2022.07.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}